このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PTC Therapeutics 将来の成長

Future 基準チェック /06

PTC Therapeuticsは、60%と7.5%でそれぞれ年率60%で利益と収益が成長すると予測される一方、EPSはgrowで60.3%年率。

主要情報

59.7%

収益成長率

60.0%

EPS成長率

Biotechs 収益成長	24.5%
収益成長率	7.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	21 Jun 2024

今後の成長に関する最新情報

Recent updates

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27

PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

Apr 11

業績と収益の成長予測

NasdaqGS:PTCT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	943	-57	250	325	9
12/31/2025	843	-203	88	46	11
12/31/2024	752	-382	-55	-193	12
3/31/2024	928	-579	-199	-58	N/A
12/31/2023	938	-627	-279	-158	N/A
9/30/2023	798	-642	-343	-224	N/A
6/30/2023	819	-618	-364	-248	N/A
3/31/2023	770	-571	-403	-289	N/A
12/31/2022	699	-559	-509	-357	N/A
9/30/2022	697	-531	-409	-260	N/A
6/30/2022	618	-556	-422	-273	N/A
3/31/2022	569	-522	-395	-249	N/A
12/31/2021	539	-524	-337	-251	N/A
9/30/2021	492	-455	-327	-247	N/A
6/30/2021	472	-391	-250	-169	N/A
3/31/2021	430	-454	-271	-213	N/A
12/31/2020	381	-438	-250	-194	N/A
9/30/2020	358	-441	-193	-140	N/A
6/30/2020	311	-432	-221	-182	N/A
3/31/2020	322	-292	-198	-138	N/A
12/31/2019	307	-252	-144	-99	N/A
9/30/2019	297	-222	-142	-104	N/A
6/30/2019	279	-213	-116	-85	N/A
3/31/2019	262	-181	-72	-54	N/A
12/31/2018	265	-128	-43	-28	N/A
9/30/2018	256	-78	0	9	N/A
6/30/2018	245	-61	-91	-10	N/A
3/31/2018	224	-69	-78	3	N/A
12/31/2017	194	-79	N/A	-10	N/A
9/30/2017	142	-107	N/A	-45	N/A
6/30/2017	123	-108	N/A	-53	N/A
3/31/2017	90	-130	N/A	-91	N/A
12/31/2016	83	-142	N/A	-104	N/A
9/30/2016	70	-166	N/A	-121	N/A
6/30/2016	57	-174	N/A	-124	N/A
3/31/2016	48	-174	N/A	-129	N/A
12/31/2015	37	-170	N/A	-124	N/A
9/30/2015	37	-147	N/A	-102	N/A
6/30/2015	29	-131	N/A	-91	N/A
3/31/2015	24	-118	N/A	-80	N/A
12/31/2014	25	-94	N/A	-57	N/A
9/30/2014	17	-84	N/A	-64	N/A
6/30/2014	32	-62	N/A	-52	N/A
3/31/2014	37	-51	N/A	-53	N/A
12/31/2013	35	-66	N/A	-47	N/A
9/30/2013	37	-48	N/A	-43	N/A
6/30/2013	28	-51	N/A	-45	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PTCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PTCT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PTCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PTCTの収益 ( 7.5% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: PTCTの収益 ( 7.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PTCTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

PTC Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

Consensus EPS estimates fall by 10%

Recent updates

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

New minor risk - Share price stability

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Price target decreased to US$51.46

Insufficient new directors

Price target decreased to US$52.31

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.

Executive VP & Chief Legal Officer exercised options and sold US$167k worth of stock

PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Executive VP & Chief Legal Officer notifies of intention to sell stock

Price target increased to US$54.64

Insider recently sold US$119k worth of stock

Consensus forecasts updated

PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates